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RAF research is booming since the discovery of mutant B-RAF in ~8% of human cancer. One reason for the excitement is the 
availability of RAF-targeted therapies. RAF inhibitors have been developed because RAF functions at a convergence point of 
signal transduction. Two recent papers by the groups of Rosen and Marais dramatically advance our understanding of RAF 
oncogenes in human tumors. The results confirm that the mitogenic cascade (RAF-MEK-ERK) is essential for RAF transforma-
tion, that RAF kinases work in concert, and that RAF-transformed cells are hooked on MEK, making them sensitive to growth 
inhibition by kinase inhibitors.Melanoma is an insidious form of skin cancer with rising inci-
dence and mortality rates. The discovery of B-RAF mutations 
in the majority of melanomas (Wellbrock et al., 2004) raised 
the hope for new therapies, as a clinically tested RAF inhibitor 
(Sorafenib) is available. However, preliminary results show lower 
than expected efficacy. Another concern stems from the finding 
that a small fraction of B-RAF mutations generates an enzyme 
that is impaired in its ability to activate the common RAF sub-
strate MEK. Alternative routes of B-RAF signaling therefore had 
to be considered. Both concerns have now largely been allevi-
ated by recent findings. A paper from the Marais group (Garnett 
et al., 2005) establishes that kinase-impaired mutants also work 
through the mitogenic cascade culminating in ERK activation. 
The mechanism is rescue of kinase-impaired mutant B-RAF by 
wild-type C-RAF through a process that involves 14-3-3-medi-
ated heterooligomerization and transactivation. Limitations of 
available RAF inhibitors seem no longer disarming because 
another publication from the Rosen lab (Solit et al., 2005) 
teaches us that V600EB-RAF-transformed human tumor cells are 
differentially sensitive to MEK inhibition.
The RAF family of protein serine/threonine kinases in mam-
mals consists of three members, A-, B-, and C-RAF. RAF kinas-
es, like their major substrate MEK, have a restricted substrate 
range (Wellbrock et al., 2004). G proteins of the Ras family 
initiate RAF activation at the plasma membrane and act through 
binding to the Ras binding domain (RBD) in the N-terminal half 
of the RAF molecule. Ras-RAF coupling leads to conformation-
al changes followed by phosphorylations (Figure 1). Although 
essential steps of this process are well established, numerous 
questions remain. RAF phosphorylation has been the most con-
troversial aspect of RAF research since the discovery of growth 
factor-induced tyrosine phosphorylation of C-RAF (Morrison et 
al., 1988). The following picture has emerged. There are three 
classes of sites for regulatory phosphorylation: docking sites 
for 14-3-3 proteins (Muslin et al., 1996), targeting sites (Alavi et 
al., 2003), and conformation relevant sites (Wan et al., 2004). 
All RAFs have at least two 14-3-3 sites, a strong C-terminal 
site and weaker internal site that differ in binding affinities by 
a factor of 10 (C-RAF). Phosphorylations that affect the active 
conformation lie in the N-terminal regulatory loop (N region) and 
in the activation segment (Figure 1). B-RAF is special in that two 
N region tyrosines present in C-RAF are occupied by aspartic 
acid. One of the two serines in this region, S338, is a targeting 
site for mitochondria (Alavi et al., 2003).
Difficulties in establishing precise roles for the various phos-cancer cell 9, January 2006 ©2006 ElsEviEr inc.     DOi 10.1016/j.ccphorylations stem from the fact that it is not a trivial task to 
purify homogeneous populations of phosphorylated RAF and 
to reconstitute RAF activation in vitro. Compounding this, RAF 
enzymes are lipophilic, and activation takes place at the mem-
brane in concert with G and 14-3-3 proteins. Regulation of RAF 
by 14-3-3 differs between isozymes and is best understood for 
C-RAF. Phosphorylation of the internal S259 and C-terminal 
S621 sites is coupled, pS259 being a prerequisite for efficient 
S621 phosphorylation. In spite of high-affinity binding, both sites 
show turnover, probably because cytosolic 14-3-3 bound RAF is 
in equilibrium with 14-3-3-depleted RAF in membranes (Hekman 
et al., 2002, 2004). Thus, membrane binding strips 14-3-3 from 
RAF proteins, allowing access to phosphatases. Phosphatase 
regulation of the internal S259 has been described by sev-
eral groups (Dhillon et al., 2002; Ory et al., 2003), although 
the details are not completely understood. A recent finding on 
the essential function of a membrane chaperone, Prohibitin, in 
the process of C-RAF activation and 14-3-3 displacement may 
shed further light on this process (Rajalingam et al., 2005). In 
any case, it is apparent that there are two populations of RAF 
in resting cells, a phosphorylated and 14-3-3 bound form in the 
cytosol and an unphosphorylated form(s) in the membrane. As 
growth factor stimulation recruits only a small percentage of 
RAF, >5% (Zhu et al., 2005), and the earliest phosphorylation 
event (in NGF-stimulated PC12 cells) targets the internal 14-
3-3 binding site, it seems likely that the pool from which RAF is 
being recruited for activation is unphosphorylated RAF in the 
plasma membrane. A tentative model has been proposed for 
the subsequent steps in the choreography of C-RAF activation 
that includes Ras-driven B- and C-RAF heterooligomerization 
and trans-phosphorylation of C-RAF on S621 and perhaps other 
sites (Hekman et al., 2004). Variations of this theme might be 
exercised in homooligomerization of B-RAF.
While 14-3-3 binding to RAF provides perhaps the best 
example for regulation of RAF by phosphorylation, there is 
evidence that N region and activation segment phosphoryla-
tion determine the magnitude of the response (Wellbrock et al., 
2004). The sites in the activation segment for which there is the 
largest consensus in the literature are T491 and S494 in C-RAF 
(Chong et al., 2001) and the corresponding positions (T599 and 
S602) in B-RAF. The finding that the most frequent activating 
mutation of B-RAF (V600E) potentially mimics phosphorylation 
at these sites supports this concept. Recently, this model was 
challenged by a study of EGF-stimulated C-RAF that used a 
combination of mass spectrometry and amino acid exchange r.2005.12.022  
	 m i n i r e v i e wat a novel site, S471 and S578, in the activation segment of C-
and B-RAF that was essential for activation (Zhu et al., 2005). 
Perhaps one shortcoming of this study is the use of in vitro-
coupled kinase activity assays, as S471 is critical for MEK1/2 
binding. Direct testing by use of biophysical methods of S471 
phosphorylation effects on conformation of the RAF kinase 
domain would have been desirable. As it stands, an alternative 
role for the function of pS471 can not be excluded where dock-
ing of MEK on RAF might be facilitated by pS471, and the bind-
ing might itself induce the active conformation. Such a model 
of substrate-assisted activation would explain why RAF kinases 
do not work well with substrate peptides and why the range of 
substrates is so small (Rapp et al., 2004). Whichever way that 
will sort out, it is clear by now that B-RAF can be activated by 
mutations in the N-terminal portion of the activation segment 
that do not mimic phosphorylation but introduce charge, and that 
there is a second cluster of mutations not in the N region or the 
Figure 1. raF activation in normal and B-raF tumor cells
a: schematic structure of B- and c-raF with regulatory phosphorylation 
sites.
B: Heterooligomerization that is thought to be associated with trans-phospho-
rylation on c-raF s621 and perhaps c-raF s471/B-raF s57. under normal 
conditions, ras induces B- and c-raF complex formation. Mutant B-raF forms 
heterooligomers in the cytosol independently of ras. it is possible that a 14-3-
3 dimer (green) is involved in crosslinking between c- and B-raF.10 internal 14-3-3 site but in the nucleotide binding loop (P loop). 
Atomic structure revealed that the P loop and N-terminal por-
tion of the activation segment normally interact via hydrophobic 
forces, thereby stabilizing the inactive conformation (Wan et al., 
2004). Most of the activating mutants disrupt this interaction and 
thereby activate the enzyme. However, at least three mutants 
(G466E, G466V, and G596R) have impaired MEK kinase activity 
in vivo (Houben et al., 2004; Wan et al., 2004). In their original 
publication describing three classes of activating B-RAF muta-
tions (high activity, intermediate activity, and kinase impaired), 
Wan et al. had already demonstrated that the kinase-impaired 
group required C-RAF for cell transformation, and both groups 
speculated that heterooligomerization of B-RAF with C-RAF 
might be the mechanism of signal transduction. In their current 
paper, Garnett et al. not only verify this proposal for crosstalk 
between mutant B- and wild-type C-RAF but also confirm and 
extend the observation of Ras-driven B- and C-RAF heteroo-
ligomerization for wild-type enzymes (Garnett et al., 2005). 
Complex formation between kinase-impaired mutant B-RAF 
and C-RAF takes place in the cytosol in a Ras-independent 
manner that requires activation segment phosphorylation and 
binding of 14-3-3 to C-RAF. Wild-type B-RAF forms a complex 
with C-RAF, in a process that is Ras dependent and takes place 
at the membrane.
By use of alanine exchange of known phosphorylation sites 
and overexpression in COS cells, Garnett et al. (2005) defined 
the requirements for activation of C-RAF by B-RAF mutants or 
by G12VRas. The C-terminal 14-3-3 binding site is essential, and 
phosphorylation sites in the activation segment T491 and S494 
play an important role for both processes. In contrast, N region 
phosphorylation is not essential for C-RAF activation by mutant 
B-RAF. The authors go on to show that cross-activation of C-
RAF by Ras-activated wild-type B-RAF or mutant B-RAF is a 
one-way street, as wild-type C-RAF or any of several activating 
C-RAF mutants do not activate B-RAF. These findings together 
with earlier data strengthen the view that heterooligomerizations 
between B- and C-RAF are important in growth factor regula-
tion of normal cells in addition to providing a route to rescue 
transforming activity of MEK kinase-impaired B-RAF mutants 
present in human tumors.
Why do we have three RAF genes in most vertebrates? 
What is the gain of function relative to the situation in insects 
and nematodes that make do with just one RAF gene? B-RAF 
is most closely related to solitary RAFs and thus is the founder 
kinase gene; A-RAF most likely was spawned by C-RAF. There 
are too many gaps in the collection of sequenced genomes 
to allow us to correlate emergence of a new RAF gene with a 
new trait. Several possibilities exist, gain of substrates and/or 
tighter control of signal flow through the cascade. There is no 
evidence that more RAF genes would translate into more RAF 
substrates. At the moment, the best guess is that having three 
RAF enzymes with widely differing basal and inducible activity 
(Emuss et al., 2005) improves fine tuning of the mitogenic cas-
cade. The principle is reminiscent of the EGF receptor family 
that has four members that differ strikingly in their regulation. 
The strongest pair is a combination of the “deaf and the dumb” 
(Citri et al., 2003) HER2 and HER3, where HER2 is ligand inde-
pendent and HER3 has an inactive kinase domain but can be 
trans-phosphorylated by HER2. RAF kinase is a progenitor in 
the evolution of (receptor) protein tyrosine kinases and may 
share some of their tricks of the trade.cancer cell January 2006 
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V600EB-RAF homodimer, although in some cell contexts this com-
plex may be too strong for induction of proliferation and instead 
drive cells into terminal differentiation (Rapp et al., 1994a; 
Traverse et al., 1994), late G1 arrest (Kerkhoff and Rapp, 1998), 
or senescence (Serrano et al., 1997; Zhu et al., 1998). Perhaps 
as a consequence the presence of V600EB-RAF is not a prog-
nostic factor for disease progression, whereas its occurrence in 
metastatic lesions predicts poor outcome (Houben et al., 2004). 
Besides the value of knowing the B-RAF status for prediction 
of disease progression, is it helpful for selection of treatment 
options? This question was addressed by Solit et al. (2005), who 
examined a panel of cancer cell lines for sensitivity toward MEK 
inhibitors. Three categories were included, one with V600EB-RAF, 
another with mutant Ras, and a third with both genes wild-type. 
Although the MEK inhibitor CI-1040 suppressed pERK in all 
lines, growth inhibition was selectively achieved in V600EB-RAF-
positive lines and less efficiently in a fraction of G12VRas lines. 
These findings are consistent with earlier data from a RAF trans-
genic mouse tumor model (Kramer et al., 2004) and a mouse 
xenograft metastasis model with a panel of V600EB-RAF-positive 
human melanoma lines (Collisson et al., 2003). The report by 
the Rosen group is the first to highlight selective sensitivity of 
human tumor cell lines. Extension of this study to the NCI 60 
cell lines for which a large body of data from inhibitor screening 
assays could be interrogated yielded supportive information, as 
the top-ranking compounds that scored on V600EB-RAF-positive 
lines happen to represent predominantly MEK inhibitors with 
similar effectiveness as CI-1040. Sensitivity to MEK inhibition 
could also be demonstrated in vivo using xenograft models and 
was not restricted to melanomas but included colon and breast 
tumor lines. In fact, in the latter case it was the observed CI-
1040 sensitivity that led to the discovery of V600EB-RAF mutation. 
It will be interesting to explore whether human B-RAF mutant 
cells also show selective sensitivity to growth inhibition by antag-
onists of downstream effectors of the mitogenic cascade as was 
observed for c-jun in mouse cells (Rapp et al., 1994b). Lack of 
responsiveness of G12VRas tumor lines or lines with wild-type 
Ras/RAF is not a total surprise, as earlier 
reports have described cell contexts that 
uncoupled Ras from the RAF-MEK-ERK 
cascade (al-Alawi et al., 1995; Repasky 
et al., 2004). Such a bypass may be 
hard-wired as part of a cell lineage- or 
developmental stage-specific program. A 
bypass may also be reversibly induced by 
hormones or growth factors (Figure 2). An example are WRT 
thyroid cells, in which treatment with thyrotropin uncoupled RAF 
from Ras through a cAMP-dependent pathway (al-Alawi et al., 
1995). Pathway switching is also known to occur in the course of 
progression of cells through a differentiating lineage; for exam-
ple, in early progenitors Ras may preferentially use PI-3 kinase 
for proliferation (Takahashi et al., 2003). The CI-1040-resistant 
tumor cell lines that carry Ras mutations and the others that 
have wild-type alleles of Ras and B-RAF may correspond to 
such early stages.
As MEK inhibitors work so well against tumor cells carry-
ing V600EB-RAF, it becomes all the more important to identify all 
tumors that are RAF dependent. Screening for the most fre-
quent B-RAF mutations may not be sufficient, since B-RAF can 
also be activated by chromosomal rearrangements and copy 
number gains. (Ciampi et al., 2005). Moreover microRNAs exist 
for all three RAF genes, making it likely that mutant RAF alleles 
with deletions in target sequences will be found in some tumors 
 (http://microrna.sanger.ac.uk/).
Attacking RAF tumors by aiming at its substrate MEK is 
one approach that now looks very promising, but RAF kinases 
themselves may have some advantages as targets. Luckily, RAF 
kinase inhibitors have been developed. The first generation is 
available as a drug for treatment of renal cancer (http://www.
onyx-pharm.com/wt/page/index/). Others will surely follow. In 
fact, there are reports on inhibitors that specifically block V600EB-
RAF (http://www.plexxikon.com/therapeutic-products.shtml).
It took 10 years to get from the discovery of RAF to delinea-
tion of the mitogenic RAF-MEK-ERK cascade and another 10 for 
development of RAF inhibitors. RAF’s relevance to human can-
cer was unambiguously established 4 years ago by the discov-
ery of frequent B-RAF mutations in >50% of melanoma and to 
a lesser extent in other malignancies. With the finding that cells 
transformed by RAF lose other options for growth control, we are 
now in the position to fight these cancers by turning the cascade 
against them. Addiction has multiple dimensions, including a 
genomic one. At the level of RAF, addiction is adduction. RAF is 
literally hooked on MEK, a situation that may also be exploited in 
Figure 2. coupling of ras to the mitogenic and 
alternate cascades
Whereas ras has a choice of different effectors 
in different cell contexts or depending on the mix 
of signals that enter the cell, raF connects with 
the MEK-ErK module upon receptor stimulation. 
Mutant raF is constitutively “hooked up” with 
MEK in the absence of receptor stimulation. The 
switch of ras to alternate effectors may corre-
late with the position of the cell in a differentiat-
ing lineage. The coupling choice of ras can be 
modified conditionally, by crosstalk with other 
signaling pathways (for example caMP regulat-
ing) or stably as part of a cellular phenotype that 
determines the mix of signaling elements.cancer cell January 2006  11
	 m i n i r e v i e wscreens for interaction blockers. It seems reasonable to expect 
that additional druggable targets are buried in this signaling 
chain. By finding them, we may be able to overcome resistance 
of individual targets and perhaps eliminate disease.
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